|Lexicon Pharmaceuticals, Inc.|
8800 Technology Forest Place
United States - Map
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes; LX1032, which is in Phase III clinical trials for the treatment of carcinoid syndrome and ulcerative colitis; and LX1033 that has completed clinical Phase II clinical trials for the treatment of irritable bowel syndrome. The company is also developing LX2931 that has completed Phase II clinical trials for the treatment of rheumatoid arthritis; and LX7101, which is in Phase I clinical trials for the treatment of glaucoma. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
|Lexicon Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Mar 1, 2014 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 7; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Arthur T. Sands M.D., Ph.D.,
Co-Founder, Chief Exec. Officer, Pres and Director
|Dr. Brian P. Zambrowicz Ph.D.,
Co-Founder, Chief Scientific Officer and Exec. VP
|Mr. Jeffrey L. Wade J.D.,
Chief Financial Officer and Exec. VP of Corp. Devel.
|Dr. Alan J. Main Ph.D.,
Exec. VP of Pharmaceutical Research
|Dr. Pablo Lapuerta M.D.,
Chief Medical Officer and Exec. VP of Clinical Devel.
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|